Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.67 – $0.97
0% from low
Exchange
OTC Link
OS
Borrow rate
0.97%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.1M | $20.2M | $11.6M | $21.7M | $23.1M | $21.7M | $21.9M | $28.8M |
| Cost of revenue | $4.2M | $7.3M | $6.5M | $9.0M | $7.0M | $7.7M | $8.8M | $17.6M |
| Gross profit | $25.0M | $12.9M | $5.1M | $12.7M | $16.1M | $14.0M | $13.1M | $11.2M |
| Gross margin | 85.7% | 64.0% | 44.2% | 58.5% | 69.7% | 64.5% | 59.7% | 39.0% |
| R&D | $6.7M | $4.3M | $3.3M | $1.8M | $2.8M | $2.4M | $3.1M | $3.2M |
| Operating income | −$1.2M | −$10.7M | −$7.3M | −$574.0K | $1.3M | −$854.0K | −$2.7M | −$6.9M |
| EBITDA | −$927.0K | −$8.8M | −$4.0M | $2.4M | $2.9M | $1.3M | $1.5M | −$4.2M |
| Net income | $3.9M | −$19.8M | −$6.9M | −$727.0K | $1.4M | −$922.0K | −$1.0M | −$7.1M |
| Net margin | 13.5% | -98.1% | -59.4% | -3.3% | 5.9% | -4.3% | -4.7% | -24.6% |
| EPS (diluted) | 0.24 | -1.32 | -0.65 | -0.07 | 0.13 | -0.09 | -0.10 | -0.68 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $21M | $0.15 | $0.15–$0.15 | 1 |
| 2028 | $18M | $-0.22 | $-0.22–$-0.22 | 1 |
| 2029 | $16M | $-0.24 | $-0.24–$-0.24 | 1 |
| 2030 | $18M | $-0.25 | $-0.25–$-0.25 | 1 |
Forward consensus · source: Financial Modeling Prep
MEDICURE INC
No one on the platform currently holds MCUJF.
No tracked institution reports a position in MCUJF as of their last filing.
No one on the platform has traded MCUJF yet.
| $3M |
| — |
| EGRXEagle Pharmaceuticals, Inc. | $0.67 | +11.67% | $9M | — |
| OASMYVivesto AB | $0.00 | +0.00% | $20606 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.3× sales vs its 0.4× historical median P/S.
Fair value ≈ $0.76 · price $0.67 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.